Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
about
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaGemcitabine eliminates double minute chromosomes from human ovarian cancer cellsQuantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancersA phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Pancreatic biomarkers: could they be the answer?Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyPharmGKB summary: gemcitabine pathwayA kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic modelsGene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine.High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Drug metabolism and pancreatic cancer.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis.Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
P2860
Q26739910-319F5756-48C8-4B3B-9CCC-B86ECD39794FQ28535582-2AC7A359-576B-42BE-A15C-9C03E1D0844FQ30579903-AEAEF154-8648-4149-A2DA-3C8BD0ECDB75Q33394505-65EBDE38-37CE-4C3F-BB25-C96B1071165EQ33684978-1F1BEEA3-48EA-40F2-8511-912184C8E2EEQ33727842-722B19BB-1492-446E-9384-13E97946C8C4Q33801371-295656F9-F368-4FE5-86B4-AE49DEFE60A3Q33914197-42DDC5CA-0068-4146-9472-1E48DB75FDC1Q34177223-78CC0C39-125D-4871-A84E-50267345B209Q34205171-313775D4-CFA7-4A79-9E2E-CA1FD1A86DFAQ34283650-9B3A45A9-02AB-4C98-80AE-6D97B03BDC1EQ34435450-F4E6E557-E0F0-45D6-BC7C-AC13CAC1AE26Q34618606-7BB18E5C-20C5-47B5-AADA-23DB0CCE95C0Q34756239-EC7C618D-6939-407B-8393-5A04D79B62A3Q34957154-0238B887-9834-47AD-B129-74813E5A65F2Q34988987-6DC34164-0A89-4153-89B8-1A7D5F108D58Q35038441-DB22E5FC-C10B-4B95-9C60-9C507ED5704FQ35242400-278D003F-B9DF-437E-A6EA-EFBC93CF0DC3Q35591895-B59021E6-8808-46F8-BB87-8CA54DB1CB6FQ35776091-418ABE6A-0D48-4CFC-A12E-6CD5F5DB2F43Q36003248-10C71DCD-3564-4242-83ED-298DEECA25CEQ36210934-B451596F-09C4-4CB5-99DA-D769FFEBCEDAQ36243941-CF2DD158-6F4C-4BAF-BE74-7BCD1D9048BDQ36796262-629832DE-35F7-4263-ADF2-CF0767088212Q36893162-2AA7B5B4-A971-4C47-8F9C-160E4343A22AQ36919830-0AFBAA93-01B7-40CE-BC99-7DA19BF18346Q36931187-9E4E54DC-44A8-45FA-8B20-F06E14830C8EQ36962474-CD01FD90-B1E9-400F-A7CF-1CC6057239C4Q37040632-350E7B11-7ABC-43F6-8CB0-2BA11477A593Q37268613-79A7CE5E-F68F-46CC-BB0B-72F83EBDC1CBQ37542844-B0A81762-568C-4FA2-844D-6E83945656E8Q37994505-046DFED3-1AD9-45E5-8A2E-F7A0DFB777B3Q38088419-0E347C67-DECB-4300-B1FA-82BED2550404Q38125770-C9939AA2-4B3E-4A70-80D8-DCA7DEF59091Q38218536-E2777E48-B86C-4033-AF04-22AC67926749Q38829129-FC6A6129-A526-44EE-9EDB-AE5743A655FAQ38914638-03EBAFFB-BC0C-464A-ADDC-C5C828AAA408Q39101616-C4F2950D-96F1-4C96-8FBA-93ECBA432F2EQ39283216-D20061F0-1278-4430-91C8-2DA449EE7E34Q40631094-C6888570-664E-49C7-8CA1-53B684E3B6D6
P2860
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@en
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@nl
type
label
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@en
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@nl
prefLabel
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@en
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
@en
P2093
I Takemasa
S Kobayashi
P2860
P2888
P304
P356
10.1038/ONC.2009.158
P407
P577
2009-06-22T00:00:00Z
P5875
P6179
1030578013